TY - JOUR A1 - Marklein, B. A1 - Jenning, M. A1 - Konthur, Zoltán A1 - Häupl, T. A1 - Welzel, F. A1 - Nonhoff, U. A1 - Krobitsch, S. A1 - Mulder, D. M. A1 - Koenders, M. I. A1 - Joshua, V. A1 - Cope, A. P. A1 - Shlomchik, M. J. A1 - Anders, H.-J. A1 - Burmester, G. R. A1 - Hensvold, A. A1 - Catrina, A. I. A1 - Rönnelid, J. A1 - Steiner, G. A1 - Skriner, K. T1 - The citrullinated/native index of autoantibodies against hnRNP-DL predicts an individual "window of treatment success" in RA patients N2 - Background: There is a need for biomarker to identify patients “at risk” for rheumatoid arthritis (risk-RA) and to better predict the therapeutic response and in this study we tested the hypothesis that novel native and citrullinated heterogeneous nuclear ribonucleoprotein (hnRNP)-DL autoantibodies could be possible biomarkers. Methods: Using protein macroarray and ELISA, epitope recognition against hnRNP-DL was analysed in sera from different developed RA disease and diagnosed SLE patients. Toll-like receptor (TLR) 7/9 and myeloid Differentiation primary response gene 88 (MyD88)-dependency were studied in sera from murine disease models. HnRNP-DL expression in cultivated cells and synovial tissue was analysed by indirect immunofluorescence, immunoblot and immunohistochemistry. KW - Citrullinated KW - Rheumatoid arthritis KW - Protein-modification KW - Autoantibodies KW - Antigens PY - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:kobv:b43-533682 SN - 1478-6362 VL - 23 SP - 1 EP - 16 PB - BioMed Central CY - London AN - OPUS4-53368 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -